Jump to content

Stephen Faraone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Keith D (talk | contribs) at 21:53, 16 December 2020 (Fix PMC warnings). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Stephen V. Faraone
Born (1956-07-27) July 27, 1956 (age 68)
NationalityUnited States
Alma materState University of New York at Stony Brook (B.A.)
University of Iowa (Ph.D.)
Brown University (Internship & Post Doctoral Programs)
Known forResearch into the nature, causes and treatment of ADHD
AwardsCHADD Hall of Fame, Chancellor's Award for Excellence in Scholarship and Creative Activities from the State University of New York, Alumni Fellow status at the University of Iowa.
Scientific career
FieldsChild psychology and psychiatry
InstitutionsHarvard Medical School

Massachusetts General Hospital

State University of New York Upstate Medical University
Doctoral advisorRichard Hurtig, Ph.D.

Stephen Vincent Faraone (born July 27, 1956)[1] is an American psychologist. He has worked mainly on attention-deficit hyperactivity disorder and related disorders.

Education and career

Faraone graduated in 1978 from the State University of New York at Stony Brook with a BA in Psychology. He then went to the University of Iowa where he obtained his Master of Arts and Doctor of Philosophy.[2] Faraone completed a postdoctoral clinical psychology internship and a research fellowship at Brown University.[3]

After completing his post-doctoral fellowship at Brown, Faraone came to the Harvard Department of Psychiatry, where he began a career in psychiatric genetics. He first served as an instructor in 1985, and as an assistant professor in 1989. He was promoted to associate professor in 1993 and Full Professor in 2002. In 2004 he moved to SUNY Upstate Medical University where he is now Distinguished Professor of Psychiatry and of Neuroscience and Physiology.[4] He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital[5] and a lecturer at Harvard Medical School. Faraone has been principal investigator on several National Institutes of Health funded grants studying the nature and causes of mental disorders in childhood. He is one of the world's leading authorities on the genetics of psychiatric disorders and has also made substantial contributions to research in psychopharmacology and research methodology.

Awards and honors

Faraone has authored over 700 journal articles,[6] editorials, chapters, and books and was the eighth highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI).[7] In 2005, ISI determined him to be the second highest cited author in the area of ADHD[8] and in 2007, he was the third most highly cited researcher in psychiatry[9] for the preceding decade. From 2014 to 2019 he has been listed as a highly cited researcher by Thomson Reuters/Clarivate Analytics.  In 2019 and 2002, his citation metrics placed him in the top 0.01% of scientists across all fields [10]

In 2002, Faraone was inducted into the CHADD Hall of Fame in recognition of outstanding achievement in medicine and education research on attention disorders. In 2004 and 2008, Faraone was elected Vice President of the International Society of Psychiatric Genetics and in 2019 he received the Paul Hoch Award from the American Psychopathological Association. In 2008, he received the SUNY Upstate President's Award for Excellence and Leadership in Research.[11] In 2019 he was elected President of the World Federation of ADHD [12]

Research Funding and Financial Disclosures

Faraone's research has been funded by the National Institute of Health, the European Union and the following pharmaceutical companies: Shire/Takeda, Ironshore, McNeil, Janssen and Sunovion. He has received income income from Shire, Rhodes, KenPharm, McNeil, Janssen, Pfizer, Eli Lilly, Sunovion, Ironshore and Novartis. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. These disclosures are routinely reported in relevant publications[13]

Books published

  • Tsuang MT, Faraone SV. The Genetics of Mood Disorders, Baltimore, MD: Johns Hopkins; 1990
  • Faraone SV, Tsuang, D, Tsuang MT. Genetics of Mental Disorders: A Guide for Students, Clinicians, and Researchers, New York, NY: Guilford;1999.
  • Faraone, S.V. Straight Talk About Your Child’s Mental Health: What To Do When Something Seems Wrong, New York, NY: Guilford, 2003.
  • Tsuang MT, Faraone SV & Glatt SG Schizophrenia: The Facts, Oxford University Press; 2011.
  • Faraone, S.V. & Antshel, K. ADHD: Non-Pharmacologic Interventions Elsevier, 2014

References

  1. ^ "Stephen Faraone CV" (PDF). SUNY Upstate. Retrieved 4 February 2019.
  2. ^ Psychiatry | SUNY Upstate Medical University
  3. ^ Psychiatry | SUNY Upstate Medical University
  4. ^ "Faculty:Psychiatry:SUNY Upstate Medical University". Retrieved 2009-05-10.
  5. ^ "About Our Department: Steve Faraone, PhD". Archived from the original on June 27, 2008. Retrieved 2009-05-10.
  6. ^ Publications - link to PubMed
  7. ^ Science, 2000, Vol 288, pg 959
  8. ^ An Interview with Dr. Stephen Faraone
  9. ^ "The Most-Cited Researchers in Psychiatry/Psychology
  10. ^ Ioannidis, John P. A.; Baas, Jeroen; Klavans, Richard; Boyack, Kevin W. (2019-08-12). "A standardized citation metrics author database annotated for scientific field". PLOS Biology. 17 (8): e3000384. doi:10.1371/journal.pbio.3000384. ISSN 1545-7885. PMC 6699798. PMID 31404057.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  11. ^ "Stephen Faraone". SUNY Upstate. Retrieved 4 February 2019.
  12. ^ "Board of the ADHD World Federation". www.adhd-federation.org. Retrieved 2020-12-16.
  13. ^ https://apsard.org/wp-content/uploads/2018/03/Faraone-2018-Disclosure.pdf